Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Current Deferred Revenue (2016 - 2026)

Biomerica's Current Deferred Revenue history spans 14 years, with the latest figure at $30000.0 for Q1 2026.

  • Quarterly results put Current Deferred Revenue at $30000.0 for Q1 2026, down 45.45% from a year ago — trailing twelve months through Feb 2026 was $30000.0 (down 45.45% YoY), and the annual figure for FY2025 was $55000.0, down 35.29%.
  • Current Deferred Revenue for Q1 2026 was $30000.0 at Biomerica, roughly flat from $30000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.2 million in Q1 2022 to a low of $30000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $60000.0 (2023), against an average of $255623.6.
  • The sharpest move saw Current Deferred Revenue plummeted 97.72% in 2022, then soared 41.67% in 2024.
  • Year by year, Current Deferred Revenue stood at $49013.0 in 2022, then increased by 22.42% to $60000.0 in 2023, then soared by 41.67% to $85000.0 in 2024, then plummeted by 64.71% to $30000.0 in 2025, then changed by 0.0% to $30000.0 in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $30000.0, $30000.0, and $54000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.